Armis Biopharma® focuses on developing antimicrobial and anti-toxin products. Its technology includes a proprietary antimicrobial agent, Veriox®, that claims to eliminate various pathogens and chemical/biological threats.

Armis Biopharma®

Armis Biopharma | 45 followers on LinkedIn. Improving Societal Health by Protecting Humans, Animals, and the Environment from Harmful and Resistant Pathogens

Global Medical Device Executive ⇨ Strategic Direction, Vision & Execution for Transformative Product Innovation & Commercialization

Michael Voss

Operations Director - Product Development at Armis Biopharma

Jamie Reese

Manager at Armis Biopharma

Angela DeVary

Armis Biopharma

Another opportunity on Thursday to share the Armis Biopharma to investment opportunity.

May 31, 2023 - Armis Biopharma Announces 510(k) Clearance for VeriCyn® Wound Wash #pressrelease #VeriCynWoundWash #ArmisBiopharma

Our very own, Randy Hubbell will be presenting the Armis Biopharma opportunity at LSI on Thursday, March 21 at 8:45am PT (track 3). Also, you can visit both Randy Hubbell and Michael Voss at the Innovators Pavilion all week. #infectioncontrol #oralhygiene #decontamination #ArmisBiopharma #ArmisBiopharmaDental #LSI2024 #LSIalumni

On September 28, 2023 Armis Biopharma Announces Receipt of a $20.3 Million Contract with the Defense Threat Reduction Agency to Develop Veriox® DECON for Battlefield Wounds #Future #ArmisBiopharma #verioxdecon #dtra #defensethreatreductionagency #warfighter

Armis Biopharma Announces the Addition of Two Key Executives to Enhance Commercialization of their Product Portfolio. @RandyHubbell @MikeVoss @TedZiemann #Future #ArmisBiopharma #HumanResources #businessintelligence #Management

Metric
Company Name	Armis Biopharma®
Symbol
MSH ID	COM:ARMISBIOPHARMA
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count
Website	armisbiopharma.com
LinkedIn	armisbiopharma
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ARMI

COM:ARMISBIOPHARMA

Armis Biopharma®

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue